We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

genOway Signs a $2 Million Contract with a US-based Biopharmaceutical Firm

Read time: Less than a minute

genOway reports the signing of a contract for up to $2 million in intended services with a leading biopharmaceutical company based in the United States of America.

Under the terms of this 2-year agreement, genOway will provide its client with customized genetically modified mouse lines tailored to the researchers’ needs. Moreover, this agreement can be increased to include additional models.

genOway has been chosen thanks to the company’s expertise and capacity to create highly sophisticated animal models by means of an industrialized production process.

"This contract is the second multi-million dollar deal of the year for genOway. It further confirms that the company is able to propose acceptable offers to large biopharmaceutical companies. genOway is proud to have been chosen by this company and we are very excited about the start of this collaboration" said Alexandre Fraichard, CEO of genOway.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.